FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1089-1091 March 9, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Demedts, M.

To the Editor: In their recent study, Demedts et al. (Nov. 24 issue)¹ report a significant difference in bone marrow toxic effects between the acetylcysteine treatment group (4 percent) and the placebo group (13 percent) (P=0.03). They postulate that this may be due to the augmentation of glutathione biosynthesis induced by acetylcysteine.

Treatment with azathioprine is known to give rise to leukopenia in up to 27 percent of patients and thrombocytopenia in up to 5 percent.² It is recognized that persons with low levels of activity of the enzyme thiopurine methyltransferase are at increased risk of bone marrow toxic effects, . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.